Molluscum contagiosum manifests as white, pink, or flesh-colored bumps on the skin.
The FDA has given its nod to cantharidin, the inaugural topical treatment for molluscum contagiosum in both adults and pediatric patients aged 2 years and above, marking a significant advancement in dermatological care.
- Cantharidin is a topical solution exclusively administered by health care professionals.
- The approval was based on two double-blind, randomized, placebo-controlled trials involving 528 participants aged 2 to 60 years.
- 54% of cantharidin-treated subjects achieved complete clearance of molluscum bumps by day 84, in contrast to 13% in the placebo group.
- Treatment was given at 21-day intervals, up to a maximum of four applications.
- Adverse events at the application site encompassed blistering, pain, itching, scabbing, reddening, discoloration, dryness, swelling, and skin erosion.
- Oral administration is contraindicated due to potential severe or fatal toxicities.
- Cantharidin offers a promising solution for molluscum contagiosum, with over half of the treated subjects achieving complete clearance, though care must be taken due to potential adverse effects.
Did You Know?
Although molluscum contagiosum is most prevalent in children aged 1-10 years, it can persist for an average of 13 months, with many cases resolving within a year even without treatment.